No. of Recommendations: 0
This is a great article. If you'd like a good summary of the company's history, its product, and the present controversy surrounding the high price of Acthar, this is it.

http://www.nytimes.com/2012/12/30/business/questcor-finds-pr...

If the article is true, I did not realize the extent to which Questcor will ensure that their expensive drug gets to those who need it. Ultimately, the entity that pays the high price is the insurer. This is not a company that is bleeding individuals dry.

One other thing that struck me again is how solid Questcor's moat is surrounding Acthar. If other companies want to bring a similar drug to the market, they will need to run the whole gambit to get theirs approved in the United States...even Synacthen, which is approved in Europe. That will take a long time and maybe is not even worth the cost.

Carl
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement